| Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Dec'16 | Sep'16 | Jun'16 | Mar'16 | Dec'15 | Sep'15 | Jun'15 | Mar'15 | Dec'14 | Sep'14 | Jun'14 | Mar'14 | Dec'13 | Sep'13 | Jun'13 | Mar'13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating activities | |||||||||||||||||||||
Net loss | |||||||||||||||||||||
- | -37,415 | - | - | - | -46,453 | -35,609 | -31,282 | -28,994 | -17,307 | -19,020 | -20,596 | -33,050 | -16,965 | -13,297 | -12,980 | -13,779 | -12,166 | -13,091 | -12,463 | -10,187 | -7,203 |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||||||||||||
Depreciation and amortization expense | |||||||||||||||||||||
5,350 | 5,365 | 5,010 | 4,666 | 4,375 | 4,466 | 4,421 | 4,292 | 4,167 | 3,069 | 3,077 | 2,954 | 2,363 | 2,206 | 2,074 | 2,118 | 2,088 | 1,915 | - | - | - | - |
Stock-based compensation expense | |||||||||||||||||||||
4,085 | 3,208 | 4,142 | 4,935 | 6,726 | 6,399 | 5,998 | 5,856 | 4,631 | 3,039 | 3,127 | 4,260 | 2,101 | 1,688 | 2,514 | 1,619 | 1,160 | 696 | - | - | - | - |
Amortization of premiums and discounts on marketable securities | |||||||||||||||||||||
- | - | 0 | 1 | -4 | -14 | -33 | -67 | -70 | -78 | - | - | - | - | - | - | - | - | - | - | - | - |
Gain on disposal of long-lived assets | |||||||||||||||||||||
- | - | 0 | 188 | 0 | 139 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation and amortization expense | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,086 | 1,043 | 1,030 |
Stock-based compensation | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2,985 | 1,309 | 686 |
Change in fair value of warrant liability | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 1,277 | 96 | 7 |
Non-cash interest expense | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | -10 | 2 | 4 | 7 | 1 | 22 | 16 | 19 |
Changes in operating assets and liabilities: | |||||||||||||||||||||
Accounts receivable | |||||||||||||||||||||
8,733 | -4,974 | 6,634 | -352 | 7,787 | -2,348 | 1,305 | -3,517 | 2,217 | 839 | -2,709 | 84 | -515 | 779 | 3,883 | -57 | -1,893 | 1,699 | 1,825 | 323 | 987 | 932 |
Receivable from Roche | |||||||||||||||||||||
2,275 | -1,059 | 7,956 | -1,880 | -787 | 2,863 | -4,810 | 4,787 | -338 | 1,965 | - | - | - | - | - | - | - | - | - | - | - | - |
Inventory | |||||||||||||||||||||
9,449 | 3,230 | 2,762 | 1,469 | -1,477 | -178 | -1,521 | 1,799 | 3,417 | -1,249 | -1,573 | 3,318 | 1,754 | -316 | 615 | 1,601 | -380 | 1,210 | 821 | 217 | -71 | -7 |
Prepaid expenses and other current assets | |||||||||||||||||||||
-7,308 | 3,143 | 4,495 | -475 | -225 | 30 | 2,239 | -856 | -1,259 | -1,429 | 397 | 445 | 2,412 | 398 | 1,398 | 319 | -108 | 264 | 42 | -54 | 51 | 403 |
Other assets | |||||||||||||||||||||
735 | -108 | -37 | -40 | -51 | -82 | -377 | 185 | 5 | -23 | -348 | 141 | 399 | 75 | 36 | 54 | 200 | -8 | 75 | 31 | -3 | -1 |
Accounts payable | |||||||||||||||||||||
175 | 3,456 | 2,702 | 1,302 | 4,152 | 278 | -490 | 753 | 2,215 | 2,582 | -5,828 | 5,721 | -461 | -991 | 1,712 | 3,484 | 1,202 | -3,279 | 1,142 | 130 | 628 | -228 |
Accrued expenses and other current liabilities | |||||||||||||||||||||
5,636 | -14,388 | 10,241 | 1,038 | 5,964 | -1,780 | 1,714 | 4,882 | 659 | 1,664 | -24 | 2,967 | -2,157 | 3,918 | 155 | 2,187 | -2,561 | 1,943 | 915 | 533 | 365 | -298 |
Deferred rent and other non-current liabilities | |||||||||||||||||||||
370 | 366 | -2,011 | 37 | -445 | 571 | 359 | 338 | 428 | 563 | 500 | -48 | -1,937 | -320 | -103 | 129 | 234 | -127 | - | - | - | - |
Deferred rent | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 785 | -29 |
Deferred revenue | |||||||||||||||||||||
7,853 | 499 | 510 | -225 | -58 | -120 | -52 | 972 | -613 | 1,080 | 262 | 328 | -56 | -157 | -932 | 150 | -277 | 481 | -412 | -986 | -111 | 649 |
Roche related-party deferred revenue | |||||||||||||||||||||
-3,389 | -981 | -3,446 | 3,446 | -3,448 | 3,453 | - | - | - | 3,512 | - | - | - | - | - | - | - | - | - | - | - | - |
Net cash used in operating activities | |||||||||||||||||||||
- | -38,892 | - | - | - | -41,644 | -17,728 | -20,643 | -18,823 | -9,973 | -11,406 | -4,157 | -37,246 | -10,917 | -13,613 | -5,466 | -10,216 | -13,441 | - | - | - | - |
Net cash used in operating activities | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7,016 | -6,694 |
Investing activities | |||||||||||||||||||||
Purchases of property and equipment | |||||||||||||||||||||
7,315 | 5,682 | 5,687 | 3,266 | 2,842 | 3,863 | 6,872 | 2,011 | 4,430 | 7,566 | 6,519 | 9,518 | 7,089 | 2,304 | 1,928 | 4,791 | 2,795 | 174 | 3,139 | 2,493 | 1,128 | 170 |
Purchases of marketable securities and other investments | |||||||||||||||||||||
- | - | 0 | 0 | 0 | 4,996 | 30,011 | 0 | 45,636 | 31,809 | - | - | - | - | - | - | - | - | - | - | - | - |
Proceeds from maturities of marketable securities | |||||||||||||||||||||
- | - | 0 | 35,000 | 15,000 | 34,390 | 40,570 | 38,000 | 44,953 | 17,500 | - | - | - | - | - | - | - | - | - | - | - | - |
Net cash (used in) provided by investing activities | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1,128 | -1,895 |
Financing activities | |||||||||||||||||||||
Change in restricted cash | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | 0 | 0 | -506 | 1,037 | - | - | - | - | - | - | - | - |
Increase in restricted cash | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 1,725 |
Net cash (used in) provided by investing activities | |||||||||||||||||||||
- | -5,682 | - | - | - | 25,531 | 3,687 | 35,989 | -5,113 | -21,875 | -121,275 | -9,518 | -6,583 | -3,341 | -1,067 | -4,791 | -2,795 | -174 | - | - | - | - |
Proceeds from indebtedness to Roche | |||||||||||||||||||||
20,000 | 30,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Proceeds from stock option exercises | |||||||||||||||||||||
1,886 | 3,430 | - | 1,617 | 617 | 1,571 | - | 219 | 160 | 143 | - | - | - | - | - | - | - | - | - | - | - | - |
Net cash provided by financing activities | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1,723 | -417 |
Proceeds from issuance of restricted stock and stock option exercises | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | 282 | 241 | 338 | 3,878 | 288 | 120 | 151 | 78 | 19 | 34 | -8 | 4 |
Proceeds from issuance of common stock from initial public offering, net of issuance costs | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 |
Payments of notes payable | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | 189 | 256 | 394 | 448 | 440 | 431 | 421 | 413 |
Net cash provided by financing activities | |||||||||||||||||||||
- | 33,430 | - | - | - | 1,571 | -189 | 219 | 160 | 143 | 282 | 241 | 245,725 | 3,878 | 99 | -136 | -243 | -370 | - | - | - | - |
Net decrease in cash, cash equivalents, and restricted cash | |||||||||||||||||||||
-6,756 | -11,144 | - | - | -11,674 | -14,542 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Effect of exchange rate changes on cash and cash equivalents | |||||||||||||||||||||
-119 | 33 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Supplemental disclosure of non-cash investing and financing activities | |||||||||||||||||||||
Net increase (decrease) in cash and cash equivalents | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | -31,705 | -132,399 | -13,434 | 201,896 | -10,380 | -14,581 | -10,393 | -13,254 | -13,985 | -13,634 | 101,962 | -9,867 | -9,006 |
Cash paid for interest | |||||||||||||||||||||
- | 891 | - | - | - | 75 | - | - | - | - | - | - | - | - | 113 | 27 | 103 | 20 | 30 | 38 | 47 | 56 |
Acquisition of property and equipment included in accounts payable and accrued expenses | |||||||||||||||||||||
7,162 | 4,528 | 1,255 | 1,596 | 551 | 696 | -3,023 | 3,111 | -156 | 2,097 | 1,117 | -761 | 1,114 | 5,352 | 22 | 685 | -1,287 | 1,914 | 2,298 | 1,518 | -855 | 955 |
Accretion of convertible preferred stock to redemption value | |||||||||||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 47 | 42 | 50 |